Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.

Sharma P, Krainer M, Saad F, Castellano D, Bedke J, Kwiatkowski M, Patnaik A, Procopio G, Wiechno P, Kochuparambil S, Thomas C, Arranz Arija JÁ, McCune SL, Hansen S, Daugaard G, Delgado Mingorance JI, Kukard C, Subudhi SK, Basu S, Jindal S, Siddiqui BA, Lako A, Gupta S, Fedorov V, Amin NP, Campos A, Wang Y, David JM, Pachynski RK

Open source

DOI: 10.1038/s41467-026-72242-w
Published: 2026 May 8
Container: Nature communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-72242-w,
  title = {Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.},
  author = {Sharma P and Krainer M and Saad F and Castellano D and Bedke J and Kwiatkowski M and Patnaik A and Procopio G and Wiechno P and Kochuparambil S and Thomas C and Arranz Arija JÁ and McCune SL and Hansen S and Daugaard G and Delgado Mingorance JI and Kukard C and Subudhi SK and Basu S and Jindal S and Siddiqui BA and Lako A and Gupta S and Fedorov V and Amin NP and Campos A and Wang Y and David JM and Pachynski RK},
  year = {2026},
  journal = {Nature communications},
  doi = {10.1038/s41467-026-72242-w},
  url = {https://doi.org/10.1038/s41467-026-72242-w}
}

RIS

TY  - JOUR
TI  - Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.
AU  - Sharma P
AU  - Krainer M
AU  - Saad F
AU  - Castellano D
AU  - Bedke J
AU  - Kwiatkowski M
AU  - Patnaik A
AU  - Procopio G
AU  - Wiechno P
AU  - Kochuparambil S
AU  - Thomas C
AU  - Arranz Arija JÁ
AU  - McCune SL
AU  - Hansen S
AU  - Daugaard G
AU  - Delgado Mingorance JI
AU  - Kukard C
AU  - Subudhi SK
AU  - Basu S
AU  - Jindal S
AU  - Siddiqui BA
AU  - Lako A
AU  - Gupta S
AU  - Fedorov V
AU  - Amin NP
AU  - Campos A
AU  - Wang Y
AU  - David JM
AU  - Pachynski RK
PY  - 2026
JO  - Nature communications
DO  - 10.1038/s41467-026-72242-w
UR  - https://doi.org/10.1038/s41467-026-72242-w
ER  -

APA

P, S., M, K., F, S., D, C., J, B., M, K., A, P., G, P., P, W., S, K., C, T., JÁ, A. A., SL, M., S, H., G, D., JI, D. M., C, K., SK, S., S, B., S, J., BA, S., A, L., S, G., V, F., NP, A., A, C., Y, W., JM, D., & RK, P. (2026). Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial.. Nature communications. https://doi.org/10.1038/s41467-026-72242-w

Source records

pubmed · retrieved 2026-09-26T08:19:41.487Z